skip to Main Content

Simplifying Testosterone Treatment

KYZATREX®:
The Next Level in
Testosterone
Replacement Therapy

Offer patients a simple, painless way to manage low testosterone with twice-daily oral capsules.

KYZATREX is helping patients ditch the painful injections and messy gels for an oral option that fits effortlessly into everyday life.

Learn More Bring KYZATREX to Your Practice
Kyzatrex Testosterone Undecanoate Bottles

Actor Portrayal

Actor Portrayal

Simplifying Testosterone Treatment

KYZATREX®:
The Next Level in
Testosterone
Replacement Therapy

Offer patients a simple, painless way to manage low testosterone with twice-daily oral capsules.

KYZATREX is helping patients ditch the painful injections and messy gels for an oral option that fits effortlessly into everyday life.

Learn More Bring KYZATREX to Your Practice
Kyzatrex Testosterone Undecanoate Bottles
Unique Formulation Card
KYZATREX 96% Effective Card
Clinically Demonstrated Safety

*In a six-month open-label clinical study (n=139) of men with low testosterone, 88% achieved Cavg 222-800 ng/dL at Day 90 (worst case scenario calculation, excluding Site 104, 95% CI, 82% to 93%). Based on end-of-study completers (n=127), 96% of patients achieved Cavg 222-800 ng/dL at Day 90 (95% CI, 93 to 99%).

An Oral Formulation of
Testosterone Undecanoate

KYZATREX is an oral formulation of testosterone undecanoate (TU) designed to utilize lymphatic absorption to bypass first-pass metabolism and drive uptake. Utilizing a self-emulsifying drug delivery system (SEDDS) incorporating phytosterol esters, KYZATREX was designed for clinical efficacy and safety.¹

Lymphatic Absorption

KYZATREX is well absorbed from the GI tract when taken with food.

Lymphatic Absorption Illustration

PK Profile1

KYZATREX is an immediate-release formulation with twice-daily dosing that, when administered every 12 hours, closely mimics the diurnal rhythm of endogenous testosterone.

Mean Concentration-Time Profile (N=139)

PK Profile Graph Image

Mean (Standard Error of the Mean) Testosterone Concentration (ng/dL) Post
Morning KYZATREX Dose at Day 90

Proven to Boost Testosterone

The efficacy of KYZATREX was evaluated in a 6-month open-label clinical study involving 139 hypogonadal men (median age of 50 years; range 22 to 66 years). The primary efficacy endpoint was the percentage of KYZATREX-treated patients with mean plasma total testosterone concentration (Cavg) over 24-hours within the normal range of 222-800 ng/dl on the final PK visit of the study at Day 90. KYZATREX demonstrated the following at Day 90:

Up Arrow Icon Smaller

Up to 96% Effective1,2* KYZATREX is clinically proven to boost testosterone levels.

Up Arrow Icon Smaller

2x Increase in Mean Free Testosterone Levels2

Down Arrow Icon Small

30% Decrease in Mean SHBG* Levels2

*Sex Hormone Binding Globulin (SHBG) binds to testosterone and decreases free testosterone levels. The less SHBG you have, the higher your free testosterone levels will be.2

Demonstrated Safety Profile

Low Blood Pressure Icon
Blood Pressure1

Endpoint

MRS-TU-2019EXT

Study (N = 155)

ABPM

Change in 24-hour mean SBP
from baseline after 4 months of
KYZATREX, mmHg (95% CI)

1.7

(0.3-3.1)

Change in 24-hour mean SBP
from baseline after 4 months of
KYZATREX, mmHg (95% CI)

1.8

(0.3-3.2)

In-clinic Blood Pressure Cuff

Change in 24-hour mean SBP
from baseline after 4 months of
KYZATREX, mmHg (95% CI)

0.2

(0.9-4.5)

Change in 24-hour mean SBP
from baseline after 4 months of
KYZATREX, mmHg (95% CI)

2.4

(0.6-4.2)

Magnifying Glass Icon
Blood Parameters1,2

(Mean ∆ from baseline at 6 months)

PSA

0.15 (±0.04) ng/mL

Hemoglobin

0.48 g/dL
Levels plateaued after 90 days of treatment

Cholesterol

11.1 mg/dL

Triglycerides

18.6 mg/dL

Fasting Insulin†

5.2 μU/mL

†Data from MRS-TU-2019 (n=162) at 12 months. MRS-TU-2019 had a different dosing scheme than MRS-TU-2019EXT.

ABPM: ambulatory blood pressure monitoring; CI: confidence interval; SBP: systolic blood pressure.

Adverse Events in ≥2% of Patients Receiving KYZATREX1

Hypertension: 2.6%

One patient discontinued because of an adverse reaction (acne).
No patients discontinued due to erythrocytosis1.

In a 12-month, open-label clinical study, men who received KYZATREX 200 mg QD to 400 mg BID (n = 202) reported the following additional adverse reactions: headache, arthralgia, diarrhea, hemoglobin increased, anxiety, constipation, peripheral edema, and prostate-specific antigen increased.1

Patient Reported Outcomes

In a clinical study, KYZATREX patients (n=214) reported the following improvements as a result of improved testosterone levels (compared to baseline):2

Exploratory endpoints from Study MRS-TU-2019; Different dosing scheme than MRS-TU-2019EXT.
Results may not be clinically significant.

Psychosexual Daily Questionnaire (PDQ)

  • Overall Level of Sexual Desire
  • Positive Mood
  • Sexual Activity Score
  • Erection Grade
  • Erection Duration
Short Form Health Survey (SF-36)
  • Fatigue
  • Energy
  • General Health
  • Social Functioning
International Index of Erectile Function (IIEF)
  • Erectile Function
  • Intercourse Satisfaction
  • Orgasmic Function
It’s All in the Delivery

Daily Oral Dosing

Testosterone-boosting benefits in two tiny capsules taken twice daily

KYZATREX is not a gel, injection, pellet, or patch. Just two KYZATREX oral doses a day help restore testosterone to normal levels and keep it there. KYZATREX should be taken with food, but no dietary modifications are required.

Flexible Dosing
Meet your patient’s testosterone needs with a range of KYZATREX doses.

KYZATREX Dosing Strengths Large

Titration Guide
Download the KYZATREX Titration Guide to understand the optimal approach for dosing and adjustments.

KYZATREX Titration Guide

References:

  1. KYZATREX  [prescribing information]. Raleigh, NC: Marius Pharmaceuticals; 2023.
  2. Data on file. Raleigh, NC: Marius Pharmaceuticals, 2020.

Important Safety Information for KYZATREX (testosterone undecanoate)
KYZATREX can increase blood pressure, which can increase the risk of having a heart attack or stroke and can increase risk of death due to a heart attack or stroke.
Your risk may be greater if you have already had a heart attack or stroke or if you have other risk factors for heart attack or stroke.

X

Leaving the Consumer Site

You are now entering a site that is for US healthcare professionals only. Products or treatments described on this site are available in the United States but may not be available in all other countries. If you are interested in becoming a KYZATREX prescriber, please enter your information below.

You can also continue to the Prescriber site now to learn more about KYZATREX and becoming a prescriber.